[go: up one dir, main page]

EP1246608A4 - PHARMAZEUTISCHE ZUBEREITUNGEN ZUR VERABREICHUNG VON WIRKSTOFFEN MIT GERINGER WASSERLöSLICHKEIT - Google Patents

PHARMAZEUTISCHE ZUBEREITUNGEN ZUR VERABREICHUNG VON WIRKSTOFFEN MIT GERINGER WASSERLöSLICHKEIT

Info

Publication number
EP1246608A4
EP1246608A4 EP00988371A EP00988371A EP1246608A4 EP 1246608 A4 EP1246608 A4 EP 1246608A4 EP 00988371 A EP00988371 A EP 00988371A EP 00988371 A EP00988371 A EP 00988371A EP 1246608 A4 EP1246608 A4 EP 1246608A4
Authority
EP
European Patent Office
Prior art keywords
drugs
delivery
pharmaceutical formulations
aqueous solubility
low aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP00988371A
Other languages
English (en)
French (fr)
Other versions
EP1246608A1 (de
Inventor
Evan C Unger
Marek J Romanowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImaRx Therapeutics Inc
Original Assignee
ImaRx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ImaRx Therapeutics Inc filed Critical ImaRx Therapeutics Inc
Publication of EP1246608A1 publication Critical patent/EP1246608A1/de
Publication of EP1246608A4 publication Critical patent/EP1246608A4/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08—Materials for coatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP00988371A 2000-01-05 2000-12-21 PHARMAZEUTISCHE ZUBEREITUNGEN ZUR VERABREICHUNG VON WIRKSTOFFEN MIT GERINGER WASSERLöSLICHKEIT Ceased EP1246608A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US47812400A 2000-01-05 2000-01-05
US478124 2000-01-05
US70348400A 2000-10-31 2000-10-31
US703484 2000-10-31
PCT/US2000/035322 WO2001049268A1 (en) 2000-01-05 2000-12-21 Pharmaceutical formulations for the delivery of drugs having low aqueous solubility

Publications (2)

Publication Number Publication Date
EP1246608A1 EP1246608A1 (de) 2002-10-09
EP1246608A4 true EP1246608A4 (de) 2005-05-18

Family

ID=27045794

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00988371A Ceased EP1246608A4 (de) 2000-01-05 2000-12-21 PHARMAZEUTISCHE ZUBEREITUNGEN ZUR VERABREICHUNG VON WIRKSTOFFEN MIT GERINGER WASSERLöSLICHKEIT

Country Status (5)

Country Link
EP (1) EP1246608A4 (de)
JP (1) JP2003520210A (de)
AU (1) AU2458501A (de)
CA (1) CA2395132A1 (de)
WO (1) WO2001049268A1 (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US7265186B2 (en) 2001-01-19 2007-09-04 Nektar Therapeutics Al, Corporation Multi-arm block copolymers as drug delivery vehicles
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
CA2466027C (en) 2001-11-07 2013-01-08 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
DE20204258U1 (de) * 2002-03-16 2003-07-31 Rübben, Alexander, Dr.med., 52074 Aachen Stent mit Beschichtung (Vitastent 2)
US20030207907A1 (en) * 2002-05-03 2003-11-06 Iversen Patrick L. Delivery of microparticle-conjugated drugs for inhibition of stenosis
US20040126400A1 (en) * 2002-05-03 2004-07-01 Iversen Patrick L. Delivery of therapeutic compounds via microparticles or microbubbles
JP2005527302A (ja) 2002-05-24 2005-09-15 アンジオテック インターナショナル アーゲー 医療用移植物をコーティングするための組成物および方法
US20040018237A1 (en) 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
AU2003267540A1 (en) * 2002-08-13 2004-02-25 Sirus Pharmaceuticals Ltd Biodegradable polymer
DE10244847A1 (de) * 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
ES2685436T3 (es) 2002-12-09 2018-10-09 Abraxis Bioscience, Llc Composiciones y procedimientos para administración de agentes farmacológicos
DE60331860D1 (en) 2002-12-30 2010-05-06 Nektar Therapeutics Mehrarmige polypeptid-poly(ethylenglykol)-blockcopolymere als arzneistoffzufuhrvehikel
AU2003303517C1 (en) * 2002-12-31 2008-04-24 Transdermal Biotechnology, Inc. Stable topical drug delivery compositions
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20040258754A1 (en) * 2003-06-18 2004-12-23 Valery Alakhov Compositions for oral administration of camptothecin and its analogs
JP4694776B2 (ja) * 2003-07-29 2011-06-08 株式会社ヤクルト本社 微小粒子組成物又はリポソーム製剤
WO2005016400A1 (en) * 2003-08-14 2005-02-24 Blue Medical Devices B.V. Endoluminal prosthesis comprising a therapeutic agent
WO2005027991A1 (en) * 2003-09-19 2005-03-31 Cambridge University Technical Services Ltd Orthopaedic devices
FR2868704B1 (fr) * 2004-04-07 2007-09-14 Ethypharm Sa Utilisation de lipides pour ameliorer la biodisponibilite de principes actifs proteiques en formulations injectables sous cutanees ou intra-musculaires
AU2005278782B2 (en) 2004-07-30 2011-04-21 Torrent Pharmaceuticals Limited Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
ES2369473T3 (es) 2004-10-07 2011-12-01 Actamax Surgical Materials Llc Adhesivo tisular polimérico basado en polisacárido para uso médico.
US8790632B2 (en) 2004-10-07 2014-07-29 Actamax Surgical Materials, Llc Polymer-based tissue-adhesive form medical use
CA2611592A1 (en) * 2005-06-17 2006-12-21 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
US8568705B2 (en) 2005-07-18 2013-10-29 Nektar Therapeutics Method for preparing branched functionalized polymers using branched polyol cores
US8679536B2 (en) 2005-08-24 2014-03-25 Actamax Surgical Materials, Llc Aldol-crosslinked polymeric hydrogel adhesives
US8679537B2 (en) 2005-08-24 2014-03-25 Actamaz Surgical Materials, LLC Methods for sealing an orifice in tissue using an aldol-crosslinked polymeric hydrogel adhesive
RU2433818C2 (ru) * 2005-08-31 2011-11-20 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Композиции, включающие слаборастворимые в воде фармацевтические вещества и противомикробные вещества
WO2007069272A2 (en) * 2005-10-21 2007-06-21 Panacea Biotec Limited Pharmaceutical composition comprising at least one anticancer drug and at least one polymer
US8916206B2 (en) 2005-12-26 2014-12-23 Ltt Bio-Pharma Co., Ltd. Nanoparticles containing water-soluble non-peptide low-molecular weight drug
JP4974533B2 (ja) * 2006-01-30 2012-07-11 富士フイルム株式会社 ジスルフィド架橋したタンパク質ナノ粒子
DE602007004124D1 (de) * 2006-08-23 2010-02-11 Blue Medical Devices B V Medizinischer stent mit einer kombination aus melatonin und paclitaxel
US9216197B2 (en) * 2006-09-11 2015-12-22 Biomas Ltd. Topical formulations of tellurium-containing compounds
CA2663558C (en) * 2006-09-26 2013-05-28 Samyang Corporation Submicron nanoparticle of poorly water soluble camptothecin derivatives and process for preparation thereof
WO2008066787A2 (en) 2006-11-27 2008-06-05 E. I. Du Pont De Nemours And Company Multi-functional polyalkylene oxides, hydrogels and tissue adhesives
US9474833B2 (en) 2006-12-18 2016-10-25 Cook Medical Technologies Llc Stent graft with releasable therapeutic agent and soluble coating
EP2156848A4 (de) * 2007-05-14 2012-11-28 Ltt Bio Pharma Co Ltd Niedermolekulares arzneimittelhaltiges nanoteilchen mit negativ geladener gruppe mit verzögerter freisetzung
DE102007036685A1 (de) 2007-08-03 2009-02-05 Innora Gmbh Verbesserte arzneimittelbeschichtete Medizinprodukte deren Herstellung und Verwendung
US8426492B2 (en) 2007-11-14 2013-04-23 Actamax Surgical Materials, Llc Oxidized cationic polysaccharide-based polymer tissue adhesive for medical use
US8497303B2 (en) * 2008-01-18 2013-07-30 Dow Global Technologies Llc Method to enhance aqueous solubility of poorly soluble actives
EP2285443B1 (de) 2008-05-01 2016-11-23 Bayer Intellectual Property GmbH Wirkstoffhafttechniken und verfahren für katheterballon
US8551136B2 (en) 2008-07-17 2013-10-08 Actamax Surgical Materials, Llc High swell, long-lived hydrogel sealant
EP2349357B1 (de) 2008-11-19 2012-10-03 Actamax Surgical Materials LLC Hydrogel-gewebeklebstoff aus aminiertem polysaccharid und aldehyd-funktionalisiertem mehrarmigen polyether
US8466327B2 (en) 2008-11-19 2013-06-18 Actamax Surgical Materials, Llc Aldehyde-functionalized polyethers and method of making same
EP2416811B1 (de) 2009-04-09 2015-09-09 Actamax Surgical Materials LLC Hydrogel-gewebekleber mit verringerter zerfallszeit
WO2011002956A1 (en) 2009-07-02 2011-01-06 E. I. Du Pont De Nemours And Company Aldehyde-functionalized polysaccharides
US8580950B2 (en) 2009-07-02 2013-11-12 Actamax Surgical Materials, Llc Aldehyde-functionalized polysaccharides
EP3925625A1 (de) * 2011-01-09 2021-12-22 ANP Technologies, Inc. Hydrophobe, molekülinduzierte und verzweigte polymeraggregate und ihre verwendung
CN103547258B (zh) 2011-03-17 2017-10-20 特兰斯德梅尔生物工艺股份有限公司 局部一氧化氮系统及其使用方法
CN107596518B (zh) 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8859705B2 (en) 2012-11-19 2014-10-14 Actamax Surgical Materials Llc Hydrogel tissue adhesive having decreased gelation time and decreased degradation time
US20190015350A1 (en) 2013-02-05 2019-01-17 Anp Technologies, Inc. Nanoparticles Containing a Taxane and their Use
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
EP3027659B1 (de) 2013-07-29 2020-12-09 Actamax Surgical Materials LLC Gewebeklebstoff mit niedriger schwellung und dichtungsmittelzusammensetzungen
CA2926797A1 (en) 2013-10-14 2015-04-23 Nanosphere Health Sciences, Llc Nanoparticle compositions and methods as carriers of nutraceutical factors across cell membranes and biological barriers
CA2970917C (en) * 2014-12-15 2019-09-17 Nanosphere Health Sciences, Llc Methods of treating inflammatory disorders and global inflammation with compositions comprising phospholipid nanoparticle encapsulations of nsaids
WO2016144376A1 (en) 2015-03-10 2016-09-15 Nanosphere Health Sciences, Llc Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
CN109715224B (zh) * 2016-09-19 2022-02-22 百多力股份公司 无聚合物的药物洗脱血管支架
CA3119037A1 (en) 2018-12-11 2020-06-18 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
CN109568271B (zh) * 2019-01-04 2021-04-30 徐州医科大学 一种pH敏感的肿瘤靶向的重组高密度脂蛋白、制备方法及应用
CN113307824B (zh) * 2021-04-26 2022-05-27 浙江大学 一种双亲性材料及其在制备脂质体中的应用
WO2024158694A1 (en) 2023-01-23 2024-08-02 Villya LLC Compositions and methods for improving the solubility of erectile dysfunction therapeutics

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766635A (en) * 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
US5830986A (en) * 1996-10-28 1998-11-03 Massachusetts Institute Of Technology Methods for the synthesis of functionalizable poly(ethylene oxide) star macromolecules
WO1998056362A1 (en) * 1997-06-12 1998-12-17 Maria Rosa Gasco Pharmaceutical composition in form of solid lipidic microparticles suitable to parenteral administration
WO1999003448A1 (en) * 1997-07-14 1999-01-28 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
WO1999014259A1 (en) * 1997-09-12 1999-03-25 Shearwater Polymers Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
WO1999015151A1 (en) * 1997-09-23 1999-04-01 University Of Utah Research Foundation Acoustically activated localized drug delivery
US5919442A (en) * 1995-08-11 1999-07-06 Dendritech, Inc. Hyper comb-branched polymer conjugates
WO1999056731A1 (en) * 1998-04-30 1999-11-11 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
US6007845A (en) * 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8403905D0 (sv) * 1984-07-30 1984-07-30 Draco Ab Liposomes and steroid esters
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5260066A (en) * 1992-01-16 1993-11-09 Srchem Incorporated Cryogel bandage containing therapeutic agent
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6004583A (en) * 1995-03-22 1999-12-21 Orex Pharmaceutical Development Corp. Protein-containing polymer composition for oral administration
US5981777A (en) * 1997-11-18 1999-11-09 The Regents Of The University Of California Recovery of taxanes from plant material

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766635A (en) * 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
US6007845A (en) * 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5919442A (en) * 1995-08-11 1999-07-06 Dendritech, Inc. Hyper comb-branched polymer conjugates
US5830986A (en) * 1996-10-28 1998-11-03 Massachusetts Institute Of Technology Methods for the synthesis of functionalizable poly(ethylene oxide) star macromolecules
WO1998056362A1 (en) * 1997-06-12 1998-12-17 Maria Rosa Gasco Pharmaceutical composition in form of solid lipidic microparticles suitable to parenteral administration
WO1999003448A1 (en) * 1997-07-14 1999-01-28 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
WO1999014259A1 (en) * 1997-09-12 1999-03-25 Shearwater Polymers Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
WO1999015151A1 (en) * 1997-09-23 1999-04-01 University Of Utah Research Foundation Acoustically activated localized drug delivery
WO1999056731A1 (en) * 1998-04-30 1999-11-11 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ADVANCED DRUG DELIVERY REVIEWS 1995 NETHERLANDS, vol. 16, no. 2-3, 1995, pages 311 - 320, ISSN: 0169-409X *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1995, TRUBETSKOY V S ET AL: "Use of polyoxyethylene-lipid conjugates as long-circulating carriers for delivery of therapeutic and diagnostic agents", XP002310887, Database accession no. EMB-1995309414 *
GANDER B ET AL: "Crosslinked Poly(alkyleneoxides) for the Preparation of Controlled Release Micromatrices", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 5, 1988, pages 271 - 283, XP002274861, ISSN: 0168-3659 *
JEONG B ET AL: "New biodegradable polymers for injectable drug delivery systems", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 62, no. 1-2, 1 November 1999 (1999-11-01), pages 109 - 114, XP004363008, ISSN: 0168-3659 *
KABANOV A V ET AL: "A NEW CLASS OF DRUG CARRIERS: MICELLES OF POLY(OXYETHYLENE)-POLY(OXYP ROPYLENE) BLOCK COPOLYMERS AS MICROCONTAINERS FOR DRUG TARGETING FROM BLOOD IN BRAIN 1", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 22, no. 2, 1 October 1992 (1992-10-01), pages 141 - 157, XP000291644, ISSN: 0168-3659 *
KWON G ET AL: "Block copolymer micelles for drug delivery: loading and release of doxorubicin", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 48, no. 2-3, 13 October 1997 (1997-10-13), pages 195 - 201, XP004125856, ISSN: 0168-3659 *
PEPPAS N A ET AL: "Poly(ethylene glycol)-containing hydrogels in drug delivery", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 62, no. 1-2, 1 November 1999 (1999-11-01), pages 81 - 87, XP004363005, ISSN: 0168-3659 *
PISTEL K F ET AL: "Biodegradable recombinant human erythropoietin loaded microspheres prepared from linear and star-branched block copolymers: Influence of encapsulation technique and polymer composition on particle characteristics", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 59, no. 3, 2 June 1999 (1999-06-02), pages 309 - 325, XP004170477, ISSN: 0168-3659 *
See also references of WO0149268A1 *
WEISSING V ET AL: "ACCUMULATION OF PROTEIN-LOADED LONG-CIRCULATING MICELLES AND LIPOSOMES IN SUBCUTANEOUS LEWIS LUNG CARCINOMA IN MICE", PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 15, no. 10, October 1998 (1998-10-01), pages 1552 - 1556, XP000942888, ISSN: 0724-8741 *

Also Published As

Publication number Publication date
AU2458501A (en) 2001-07-16
CA2395132A1 (en) 2001-07-12
WO2001049268A1 (en) 2001-07-12
JP2003520210A (ja) 2003-07-02
EP1246608A1 (de) 2002-10-09

Similar Documents

Publication Publication Date Title
EP1246608A4 (de) PHARMAZEUTISCHE ZUBEREITUNGEN ZUR VERABREICHUNG VON WIRKSTOFFEN MIT GERINGER WASSERLöSLICHKEIT
IL149186A0 (en) Pharmaceutical compositions providing enhanced drug concentrations
MXPA03004941A (es) Formulacion farmacologica que tiene tolerancia por via oral mejorada.
EP1239831A4 (de) Verbesserte pharmazeutische zusammensetzungen für schwerlösliche arzneistoffe
AU2002239282A1 (en) Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
PL351526A1 (en) Pharmaceutical formulation comprising amoxycillin
AU2001283563A1 (en) Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
HUP0301921A3 (en) Sustained release pharmaceutical compositions for paranteral administration of hydrophilic compounds
IL151910A0 (en) Compositions for drug delivery
HUP0301177A3 (en) Ion-strength independent sustained release pharmaceutical formulation
AU3408901A (en) Cancer remedy comprising anthranilic acid derivative as active ingredient
EP1221926A4 (de) Pharmazeutische zusammensetzungen mit schlecht löslichen arzneimittelwirkstoffen
IL154268A0 (en) Improved solid pharmaceutical dosage formulation of hydrophobic drugs
IL148725A0 (en) Aqueous pharmaceutical compositions containing circlesonide
AU2002346457A8 (en) Pharmaceutical formulations comprising indolinone derivatives
EP1142565A4 (de) Wässerige arzneimittel
AU2001260089A1 (en) Pharmaceutical compositions comprising desglymidodrine as an active drug substance
EP1448203A4 (de) Pharmazeutische formulierungen mit substituierten xanthin-verbindungen
HUP0303089A3 (en) Stable pharmaceutical form of an anticancer drug
IL155855A0 (en) Pharmaceutical formulation of gepirone for oral administration
GB0014851D0 (en) Novel pharmaceutical formulation
HUP0303714A3 (en) Pharmaceutical compositions for dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient
AU2001264129A1 (en) Novel aqueous anti-inflammatory pharmaceutical formulation
AU2001274231A1 (en) Novel aqueous anti-inflammatory pharmaceutical formulation
GB0014883D0 (en) Novel pharmaceutical formulation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020731

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

RBV Designated contracting states (corrected)

Designated state(s): DE FR GB IT

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 9/127 B

Ipc: 7A 61K 9/19 B

Ipc: 7A 61K 9/14 A

Ipc: 7A 61K 9/51 B

Ipc: 7A 61K 47/48 B

Ipc: 7A 61K 9/10 B

Ipc: 7A 61K 9/107 B

A4 Supplementary search report drawn up and despatched

Effective date: 20050401

17Q First examination report despatched

Effective date: 20050616

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20070309